Kornitzer Capital Management Inc. KS Purchases 3,167 Shares of Krystal Biotech, Inc. $KRYS

Kornitzer Capital Management Inc. KS grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 24.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,293 shares of the company’s stock after acquiring an additional 3,167 shares during the period. Kornitzer Capital Management Inc. KS owned about 0.06% of Krystal Biotech worth $5,418,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of KRYS. Parallel Advisors LLC boosted its stake in Krystal Biotech by 2.0% during the 3rd quarter. Parallel Advisors LLC now owns 1,733 shares of the company’s stock valued at $576,000 after acquiring an additional 34 shares during the last quarter. Signaturefd LLC increased its position in shares of Krystal Biotech by 27.3% in the 3rd quarter. Signaturefd LLC now owns 168 shares of the company’s stock worth $56,000 after purchasing an additional 36 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Krystal Biotech by 0.9% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company’s stock worth $1,537,000 after purchasing an additional 53 shares during the last quarter. Hanseatic Management Services Inc. raised its stake in shares of Krystal Biotech by 2.0% in the 3rd quarter. Hanseatic Management Services Inc. now owns 3,183 shares of the company’s stock valued at $1,059,000 after purchasing an additional 63 shares in the last quarter. Finally, Heritage Family Offices LLP acquired a new stake in shares of Krystal Biotech in the 3rd quarter valued at about $25,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the sale, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $300.88 on Monday. Krystal Biotech, Inc. has a 1 year low of $192.52 and a 1 year high of $382.54. The stock has a fifty day moving average of $332.48 and a two-hundred day moving average of $309.12. The firm has a market capitalization of $8.92 billion, a PE ratio of 40.83 and a beta of 0.56.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.26. The company had revenue of $127.34 million during the quarter, compared to analyst estimates of $125.77 million. Krystal Biotech had a net margin of 47.91% and a return on equity of 17.02%. Equities research analysts predict that Krystal Biotech, Inc. will post 7.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on KRYS shares. HC Wainwright reaffirmed a “buy” rating and issued a $361.00 price objective on shares of Krystal Biotech in a report on Thursday, October 15th. The Goldman Sachs Group began coverage on shares of Krystal Biotech in a report on Thursday, September 24th. They set a “buy” rating and a $441.00 target price on the stock. TD Cowen reduced their price target on shares of Krystal Biotech from $403.00 to $380.00 and set a “buy” rating on the stock in a research report on Tuesday, November 3rd. Zacks Research lowered shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a report on Friday, October 23rd. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and a consensus price target of $375.00.

Krystal Biotech Profile

Krystal Biotech, Inc is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells.

Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.